share_log

Virpax Pharmaceuticals | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Virpax Pharmaceuticals | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Virpax製藥 | S-1/A：證券上市註冊聲明(修正)
美股SEC公告 ·  08/13 09:07

Moomoo AI 已提取核心訊息

Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed an amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on August 13, 2024. The company is offering up to 6,422,018 shares of common stock and an equal number of pre-funded warrants to purchase common stock. The offering is being conducted on a best-efforts basis by RBW Capital Partners LLC, acting through Dominari Securities LLC, as the sole placement agent. The offering is expected to close one business day after commencement, with the securities delivered upon receipt of investor funds. Virpax intends to use the net proceeds for the development of its product candidate Probudur, working capital, and other general corporate purposes. The company's...Show More
Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed an amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on August 13, 2024. The company is offering up to 6,422,018 shares of common stock and an equal number of pre-funded warrants to purchase common stock. The offering is being conducted on a best-efforts basis by RBW Capital Partners LLC, acting through Dominari Securities LLC, as the sole placement agent. The offering is expected to close one business day after commencement, with the securities delivered upon receipt of investor funds. Virpax intends to use the net proceeds for the development of its product candidate Probudur, working capital, and other general corporate purposes. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'VRPX'. The announcement also details the company's recent developments, including a settlement agreement with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc., compliance with Nasdaq's Minimum Stockholders' Equity Rule, and positive results from a Swine Model pilot study for Probudur.
Virpax製藥公司（Virpax）是一家處於臨床前階段的製藥公司，於2024年8月13日向證券交易委員會（SEC）提交了S-1表格登記聲明的修訂版本。 公司最多提供6,422,018股普通股和同等數量的預先認購普通股的權證。該發行是由RBW Capital Partners LLC通過唯一放置代理Dominari Securities LLC盡力進行的。發行預計在開始一天後的一個工作日內結束，證券將在接收投資者資金後交付。Virpax打算將淨收益用於其前瞻性產品Probudur的開發、營運資本和其他一般企業用途。 公司的普通股在納斯達克交易所上市，股票代碼爲「VRPX」。 公告還詳細說明了公司的最新發展情況，包括與Sorrento Therapeutics, Inc.和Scilex Pharmaceuticals Inc.的結算協議、符合納斯達克最低股東權益規定和Probudur豬模型試驗的積極結果。
Virpax製藥公司（Virpax）是一家處於臨床前階段的製藥公司，於2024年8月13日向證券交易委員會（SEC）提交了S-1表格登記聲明的修訂版本。 公司最多提供6,422,018股普通股和同等數量的預先認購普通股的權證。該發行是由RBW Capital Partners LLC通過唯一放置代理Dominari Securities LLC盡力進行的。發行預計在開始一天後的一個工作日內結束，證券將在接收投資者資金後交付。Virpax打算將淨收益用於其前瞻性產品Probudur的開發、營運資本和其他一般企業用途。 公司的普通股在納斯達克交易所上市，股票代碼爲「VRPX」。 公告還詳細說明了公司的最新發展情況，包括與Sorrento Therapeutics, Inc.和Scilex Pharmaceuticals Inc.的結算協議、符合納斯達克最低股東權益規定和Probudur豬模型試驗的積極結果。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間